B

HLB제넥스

187420KOSDAQ

69.5 / 100

Reference Date: 2026-09-08

Financial Score31.5 / 40
News Sentiment18.0 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but ROE is below the industry average. Surged 17.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

HLB제넥스 is a biotech company founded in 2000, specializing in the development and production of customized enzymes and bio-healthcare materials using core technologies like microbial display and recombinant protein secretion. Its main business areas include industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme products, with key offerings such as eco-friendly catalase, lactase for GOS production, and nattokinase for cardiovascular health. The company is also advancing its pipeline drug GF103, an oral treatment for wet age-related macular degeneration, currently preparing for Phase I clinical trials.

Number of Employees

82people

Average Salary

57.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
2.53Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
1.17Industry Average 1.204.0Point

In line with industry avg

ROE
55.20Industry Average 8.007.0Point

6.9x industry avg (excellent)

Debt Ratio
33.29Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲26.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲122.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.4% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 1Negative 1Average Sentiment Score 72

Detailed Momentum

52-week position3.0Point

52w lower range (29%)

Current 1,959Won52-week high 3,34552-week low 1,373
1-month return6.0Point

1m +17.52% (strong rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-14
  • Neutral반기보고서 (2026.06)2026-08-13